BR112013019540A2 - formulações de pó seco de partículas que contêm dois ou mais ingredientes ativos para o tratamento de doenças obstrutivas ou inflamatórias das vias aéreas - Google Patents
formulações de pó seco de partículas que contêm dois ou mais ingredientes ativos para o tratamento de doenças obstrutivas ou inflamatórias das vias aéreasInfo
- Publication number
- BR112013019540A2 BR112013019540A2 BR112013019540A BR112013019540A BR112013019540A2 BR 112013019540 A2 BR112013019540 A2 BR 112013019540A2 BR 112013019540 A BR112013019540 A BR 112013019540A BR 112013019540 A BR112013019540 A BR 112013019540A BR 112013019540 A2 BR112013019540 A2 BR 112013019540A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- obstructive
- powder formulations
- inflammatory airway
- active ingredients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0082—Lung surfactant, artificial mucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
Abstract
formulações de pó seco de partículas que contêm dois ou mais ingredientes ativos para o tratamento de doenças obstrutivas ou inflamatórias das vias aéreas a invenção refere-se a formulações de pó seco para inalação compreendendo partículas secas por aspersão e seu uso no tratamento de uma doença obstrutiva ou inflamatória das vias aéreas. cada partícula tem um núcleo de um primeiro ingrediente ativo em forma substancialmente cristalina que é revestido com uma camada de um segundo ingrediente ativo em forma substancialmente amorfa que está disperso em um excipiente hidrofóbico farmaceuticamente aceitável. a invenção refere-se também a um processo para a preparação de tais formulações.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161439527P | 2011-02-04 | 2011-02-04 | |
US61/439,527 | 2011-02-04 | ||
PCT/US2012/023727 WO2012106575A1 (en) | 2011-02-04 | 2012-02-03 | Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013019540A2 true BR112013019540A2 (pt) | 2016-10-04 |
BR112013019540B1 BR112013019540B1 (pt) | 2021-08-17 |
Family
ID=45722714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013019540-1A BR112013019540B1 (pt) | 2011-02-04 | 2012-02-03 | Formulação de pó seco para inalação, seu uso, e sistema de liberação |
Country Status (17)
Country | Link |
---|---|
US (1) | US9050267B2 (pt) |
EP (1) | EP2670395B1 (pt) |
JP (2) | JP5791737B2 (pt) |
KR (1) | KR101580728B1 (pt) |
CN (1) | CN103347501B (pt) |
AR (1) | AR085120A1 (pt) |
AU (1) | AU2012212094B2 (pt) |
BR (1) | BR112013019540B1 (pt) |
CA (1) | CA2825576C (pt) |
ES (1) | ES2539612T3 (pt) |
JO (1) | JOP20120023B1 (pt) |
MX (1) | MX354109B (pt) |
PL (1) | PL2670395T3 (pt) |
PT (1) | PT2670395E (pt) |
RU (1) | RU2629333C2 (pt) |
TW (1) | TWI519319B (pt) |
WO (1) | WO2012106575A1 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
WO2014007772A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising glucose anhydrous |
WO2014007771A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising muscarinic receptor antagonist |
WO2014007766A1 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose |
EA201590030A1 (ru) * | 2012-07-05 | 2015-09-30 | Арвен Айлак Санайи Ве Тиджарет А.С. | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент |
US9815815B2 (en) | 2013-01-10 | 2017-11-14 | Pulmokine, Inc. | Non-selective kinase inhibitors |
CN104955448A (zh) * | 2013-01-31 | 2015-09-30 | 普罗索尼克斯有限公司 | 适用于吸入治疗的包含多组分结晶颗粒的药物组合物 |
GB201301721D0 (en) * | 2013-01-31 | 2013-03-20 | Prosonix Ltd | Pharmaceutical Preparations |
US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
AU2014229361B2 (en) * | 2013-03-14 | 2016-08-04 | Novartis Ag | Deamorphization of spray-dried formulations via spray-blending |
EP3054937B1 (en) * | 2013-10-11 | 2023-07-26 | Pulmokine, Inc. | Spray dry formulations |
GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
GB201321712D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
CA2977083A1 (en) * | 2014-02-20 | 2015-08-27 | Kambiz Yadidi | Dry powder formulations for inhalation |
CA2940599A1 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients |
GB201408387D0 (en) * | 2014-05-12 | 2014-06-25 | Teva Pharmaceuticals Europ B V | Treatment of respiratory disorders |
CN107106641B (zh) | 2014-10-31 | 2021-12-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 粉末制剂 |
CA2967039A1 (en) * | 2014-11-10 | 2016-05-19 | National Institutes Of Health | Probiotic therapeutic applications |
CN104758294A (zh) * | 2014-12-17 | 2015-07-08 | 广州呼吸疾病研究所 | 用于copd、哮喘治疗的吸入药物组合物及其制备方法 |
CA2992171A1 (en) * | 2015-09-09 | 2017-03-16 | Novartis Ag | Targeted delivery of spray-dried formulations to the lungs |
JP2020500183A (ja) | 2016-10-27 | 2020-01-09 | プルモキネ、インコーポレイテッド | 肺高血圧症の治療のための併用療法 |
CN111526870A (zh) * | 2018-01-26 | 2020-08-11 | 诺华股份有限公司 | 吸入治疗药物的高剂量递送 |
JP2022536415A (ja) * | 2019-06-10 | 2022-08-16 | レスピラ セラピューティクス インコーポレイテッド | 担体ベースの製剤及び関連する方法 |
CN110724095B (zh) * | 2019-09-12 | 2023-06-09 | 上海方予健康医药科技有限公司 | 一种茚达特罗乙酸盐的制备方法 |
US11083693B1 (en) | 2020-01-20 | 2021-08-10 | Cai Gu Huang | Liposome formulation of vilanterol trifenatate |
WO2021219495A1 (en) | 2020-04-28 | 2021-11-04 | Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch | Methods for treating or preventing a viral infection or inhibiting viral replication |
CN114344285B (zh) * | 2020-10-14 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 改良的可吸入团聚物 |
EP4228643A1 (en) * | 2020-10-15 | 2023-08-23 | National University Hospital (Singapore) Pte Ltd | Composition and methods for the prevention and treatment of covid-19 and respiratory illnesses |
WO2023247952A1 (en) * | 2022-06-21 | 2023-12-28 | Hovione Scientia Limited | Crystalline pharmaceutical composition for inhalation comprising sugar and lipid composite particles and process for manufacture |
WO2024009079A1 (en) * | 2022-07-04 | 2024-01-11 | Hovione Scientia Limited | Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US736102A (en) | 1902-09-25 | 1903-08-11 | Andrew F Howe | Molding car-wheels. |
US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
DE3260474D1 (en) | 1981-02-02 | 1984-09-06 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
AU661857B2 (en) | 1991-06-26 | 1995-08-10 | Merck Sharp & Dohme Corp. | Inhalation device for powdered medicaments |
ATE222754T1 (de) * | 1992-06-12 | 2002-09-15 | Teijin Ltd | Ultrafeines pulver zur inhalation und dessen herstellung |
MY115140A (en) | 1992-12-18 | 2003-04-30 | Schering Corp | Inhaler for powdered medications |
US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
ES2302332T3 (es) | 1994-09-21 | 2008-07-01 | Nektar Therapeutics | Aparato y metodos para dispersar medicamentos en polvo seco. |
TR199801265T2 (xx) | 1996-01-03 | 1998-10-21 | Glaxo Group Limited | ��e soluma cihaz�. |
AU714886B2 (en) | 1996-02-21 | 2000-01-13 | Merck Sharp & Dohme Corp. | Powdered medication inhaler |
US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
RU2238936C2 (ru) | 1996-11-11 | 2004-10-27 | Кристиан Р. НОЕ | Энантиомерно чистые основные эфиры арил-циклоалкилгидроксикарбоновых кислот, способ их получения и применение в лекарственных средствах |
US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
US6638621B2 (en) | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
SE9802073D0 (sv) * | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
UA73924C2 (en) | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
AU764541B2 (en) | 1999-05-28 | 2003-08-21 | Novartis Ag | Apparatus and method for dispensing metered amount of aerosolized medication |
GB9928311D0 (en) * | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
US20010029947A1 (en) | 1999-12-17 | 2001-10-18 | Steve Paboojian | Receptacles to facilitate the extraction of powders |
US7069929B2 (en) | 2000-02-01 | 2006-07-04 | Quadrant Technologies Limited | Dry powder inhaler |
GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
TWI290473B (en) | 2000-05-10 | 2007-12-01 | Alliance Pharma | Phospholipid-based powders for drug delivery |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
GB0020616D0 (en) | 2000-08-21 | 2000-10-11 | Quadrant Holdings Cambridge | Particulates |
FI20002215A0 (fi) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
FI20002216A0 (fi) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit astman hoitoon |
GB0030074D0 (en) | 2000-12-08 | 2001-01-24 | Univ London Pharmacy | Particulate inhalation carrier |
AU2002335046A1 (en) | 2001-10-19 | 2003-05-06 | Inhale Therapeutic Systems, Inc. | The use of proton sequestering agents in drug formulations |
AU2003219788A1 (en) | 2002-02-13 | 2003-09-04 | Dana-Farber Cancer Institute, Inc. | METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1Alpha- |
GB0208609D0 (en) * | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Compositions |
JP2006513236A (ja) | 2002-12-31 | 2006-04-20 | ネクター セラピューティクス | 不溶性活性物質を伴う医薬製剤 |
WO2004098561A2 (en) | 2003-05-08 | 2004-11-18 | Nektar Therapeutics Uk Ltd | Particulate materials |
MXPA05012821A (es) | 2003-05-28 | 2006-02-13 | Nektar Therapeutics | Formulacion farmaceutica que comprende un agente activo insoluble en agua. |
SE527191C2 (sv) | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av tiotropium och fluticason |
US20050048127A1 (en) | 2003-07-22 | 2005-03-03 | Larry Brown | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
GB0317374D0 (en) | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
CA2540005A1 (en) | 2003-09-26 | 2005-04-07 | Schering Corporation | Pulmonary disease treatment |
GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
BRPI0507884A (pt) | 2004-02-24 | 2007-08-07 | Microdose Technologies Inc | método e equipamento para administração de medicamento com base em jato sintético |
US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
BRPI0512326A (pt) | 2004-06-21 | 2008-02-26 | Nektar Therapeutics | composições compreendendo anfotericina b, métodos e sistemas |
GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
GB0416694D0 (en) | 2004-07-27 | 2004-09-01 | Univ Strathclyde | Process for preparing microcrystals |
AU2006272438B2 (en) * | 2005-07-15 | 2011-08-04 | Map Pharmaceuticals, Inc. | Method of particle formation |
CA2615378C (en) | 2005-07-15 | 2015-02-17 | Map Pharmaceuticals, Inc. | Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof |
GB0600238D0 (en) | 2006-01-06 | 2006-02-15 | Sandoz Ag | Organic compounds |
JP2007277057A (ja) | 2006-04-07 | 2007-10-25 | Mitsubishi Pencil Co Ltd | 結晶性酸化チタン膜被覆紛体及びその製造方法 |
GB0610090D0 (en) | 2006-05-20 | 2006-06-28 | Price Robert | Particulate drug compositions and their uses |
ES2396987T3 (es) | 2006-06-30 | 2013-03-01 | Novartis Ag | Derivados de quinolina y sus composiciones farmacéuticas |
US20080085315A1 (en) | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
US8573197B2 (en) | 2006-10-25 | 2013-11-05 | Novartis Ag | Powder dispersion apparatus, method of making and using the apparatus, and components that can be used on the apparatus and other devices |
WO2008066298A1 (en) | 2006-11-27 | 2008-06-05 | Mazence Inc. | Compound for treatment or prevention of prostate-related diseases and pharmaceutical composition of colon delivery system containing the same |
CA2623560A1 (en) | 2007-02-28 | 2008-08-28 | Ranbaxy Laboratories Limited | A process for preparing stable amorphous benzimidazole composition |
TWI405590B (zh) * | 2007-04-06 | 2013-08-21 | Activus Pharma Co Ltd | 微粉碎化有機化合物粒子之製法 |
CN101342155B (zh) * | 2007-07-11 | 2012-01-04 | 天津帝士力投资控股集团有限公司 | 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法 |
WO2009117112A2 (en) | 2008-03-21 | 2009-09-24 | Novartis Ag | Powder dispersion apparatus, method of making and using the apparatus, components that can be used on the apparatus and other devices, and various active agents |
US20100120737A1 (en) | 2008-11-10 | 2010-05-13 | Martin Feth | Amorphous ciclesonide |
JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
-
2012
- 2012-02-01 JO JOP/2012/0023A patent/JOP20120023B1/ar active
- 2012-02-02 AR ARP120100342A patent/AR085120A1/es unknown
- 2012-02-03 RU RU2013140706A patent/RU2629333C2/ru active
- 2012-02-03 US US13/982,630 patent/US9050267B2/en active Active
- 2012-02-03 TW TW101103574A patent/TWI519319B/zh active
- 2012-02-03 CN CN201280007762.3A patent/CN103347501B/zh active Active
- 2012-02-03 CA CA2825576A patent/CA2825576C/en active Active
- 2012-02-03 JP JP2013552665A patent/JP5791737B2/ja active Active
- 2012-02-03 MX MX2013008796A patent/MX354109B/es active IP Right Grant
- 2012-02-03 ES ES12705203.3T patent/ES2539612T3/es active Active
- 2012-02-03 EP EP12705203.3A patent/EP2670395B1/en active Active
- 2012-02-03 AU AU2012212094A patent/AU2012212094B2/en active Active
- 2012-02-03 KR KR1020137023293A patent/KR101580728B1/ko active IP Right Grant
- 2012-02-03 BR BR112013019540-1A patent/BR112013019540B1/pt active IP Right Grant
- 2012-02-03 WO PCT/US2012/023727 patent/WO2012106575A1/en active Application Filing
- 2012-02-03 PT PT127052033T patent/PT2670395E/pt unknown
- 2012-02-03 PL PL12705203T patent/PL2670395T3/pl unknown
-
2015
- 2015-05-13 JP JP2015098187A patent/JP6082049B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2012106575A1 (en) | 2012-08-09 |
AR085120A1 (es) | 2013-09-11 |
JP6082049B2 (ja) | 2017-02-15 |
US20130319411A1 (en) | 2013-12-05 |
ES2539612T3 (es) | 2015-07-02 |
JP2014507432A (ja) | 2014-03-27 |
TWI519319B (zh) | 2016-02-01 |
JP5791737B2 (ja) | 2015-10-07 |
AU2012212094A8 (en) | 2013-12-05 |
KR20130115380A (ko) | 2013-10-21 |
KR101580728B1 (ko) | 2015-12-28 |
PT2670395E (pt) | 2015-07-21 |
CN103347501A (zh) | 2013-10-09 |
CA2825576C (en) | 2020-07-14 |
MX354109B (es) | 2018-01-16 |
TW201309348A (zh) | 2013-03-01 |
EP2670395A1 (en) | 2013-12-11 |
BR112013019540B1 (pt) | 2021-08-17 |
EP2670395B1 (en) | 2015-03-25 |
MX2013008796A (es) | 2013-09-06 |
AU2012212094B2 (en) | 2016-02-11 |
CA2825576A1 (en) | 2012-08-09 |
CN103347501B (zh) | 2015-11-25 |
JOP20120023B1 (ar) | 2022-03-14 |
PL2670395T3 (pl) | 2015-08-31 |
AU2012212094A1 (en) | 2012-08-09 |
JP2015187124A (ja) | 2015-10-29 |
RU2629333C2 (ru) | 2017-08-28 |
RU2013140706A (ru) | 2015-03-10 |
US9050267B2 (en) | 2015-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013019540A2 (pt) | formulações de pó seco de partículas que contêm dois ou mais ingredientes ativos para o tratamento de doenças obstrutivas ou inflamatórias das vias aéreas | |
CL2015002632A1 (es) | Aglomerados respirables de partículas de vehículo porosas y fármaco micronizado | |
BR112013007304A2 (pt) | pós secos de cátion de metal monovalente para inalação | |
FI3125875T3 (fi) | Inhaloitava rapamysiiniformulaatio ikäsidonnaisten tilojen hoitoon | |
NI201800066A (es) | Derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios relacionados con el sueño. | |
UY37773A (es) | Imidazopirimidinas diazabicíclicas sustituidas y su uso | |
UY37328A (es) | Compuestos diazaheterobicíclicos sustituidos y su uso | |
BRPI1014275B8 (pt) | composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos | |
HRP20160373T1 (hr) | Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava | |
BR112015021583A8 (pt) | forma de dosagem oral sólida, seu processo de preparação e uso de uma pluralidade de partículas | |
BR112016003229A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
CO6640319A2 (es) | Formulación en polvo seca que comprende una droga antimuscarínica | |
PE20141036A1 (es) | Nueva dosificacion y formulacion | |
PE20141703A1 (es) | Formulacion seca en polvo que comprende un corticoesteroide y un beta-adrenergico para administrar por inhalacion | |
BRPI1014278B8 (pt) | método para produzir uma forma de dosagem compreendendo metaxolona, forma de dosagem, composição farmacêutica compreendendo a referida forma de dosagem e uso da mesma | |
AR091161A1 (es) | Composicion farmaceutica para inhalacion, metodo, uso | |
BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
BR112014029735A2 (pt) | forma de dosagem e formulação de abediterol | |
BR112015020443A2 (pt) | desamorfização de formulações secadas por atomização via mistura por atomização | |
BR112015021525A2 (pt) | composições farmacêuticas secas compreendendo nanopartículas de agente ativo ligadas a partículas de tansportadores | |
RU2016103313A (ru) | Липидная наночастица с полимиксином | |
BR112022022081A2 (pt) | Composição farmacêutica inalável, método para tratar uma infecção viral pulmonar, pó seco inalável, composição farmacêutica, sistema de inalação para o uso no tratamento ou profilaxia de uma infecção viral pulmonar | |
BR112017007182A2 (pt) | composição compreendendo ao menos um pó seco obtido por secagem por atomização para aumentar a estabilidade da formulação | |
Thomas et al. | Development of a dry powder aerosol for the dispersion and eradication of respiratory biofilms | |
CO2017004512A2 (es) | Composición farmacéutica que contiene budesonida y formoterol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2012, OBSERVADAS AS CONDICOES LEGAIS. |